Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial
Lovas K, Gebre-Medhin G, Trovik TS, Fougner KJ, Uhlving S, Nedrebo BG, Myking OL, Kampe O, Husebye ES
Published in Journal of Clinical Endocrinology & Metabolism
Methodology
Randomised double-blind parallel-group trial of 25 mg/day DHEA versus placebo for 9 months in patients with primary and secondary adrenal failure.
Key Findings
DHEA normalised serum androgen levels but produced no significant improvement in subjective health status, fatigue or sexuality versus placebo.
Conclusions
DHEA replacement in adrenal failure did not improve wellbeing despite restoring androgen concentrations.
Limitations
Moderate sample size; single-country cohort; possible insensitivity of quality-of-life instruments.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.